Table 5 Numbers of treated patients and prevalence of drugs prescription based on serum iPTH (pg/ml) and Ca (mmol/l) levels
Therapy | iPTH<120 n=1849 | iPTH 120–540 n=2436 | iPTH>540 n=723 | |||
|---|---|---|---|---|---|---|
Ca≤2.4 n=1380 | Ca>2.4 n=469 | Ca≤2.4 n=2141 | Ca>2.4 n=295 | Ca≤2.4 n=586 | Ca>2.4 n=137 | |
Calcimimetic | 13 (0.9 %) | 2 (0.4 %) | 64 (3.0 %) | 14 (4.7 %) | 133 (22.7 %) | 33 (24.1 %) |
Ca-PO4 binder | 567 (41.1 %) | 202 (43.1 %) | 886 (41.4 %) | 95 (32.2 %) | 223 (38.1 %) | 38 (27.7 %) |
Non Ca-PO4 binder | 155 (11.2 %) | 64 (13.6 %) | 383 (17.9 %) | 85 (28.8 %) | 207 (35.3 %) | 53 (38.7 %) |
Native vitamin D | 28 (1.5 %) | 7 (0.4 %) | 93 (3.8 %) | 2 (0.08 %) | 32 (4.4 %) | 4 (0.6 %) |
Active vitamin D analogs | 324 (24 %) | 143 (31.6 %) | 964 (45.6 %) | 155 (52.94 %) | 359 (62.3 %) | 75 (57.1 %) |
No therapy | 544 (39.4 %) | 152 (32.4 %) | 527 (24.6 %) | 60 (20.3 %) | 51 (8.7 %) | 15 (10.9 %) |